Rüschoff, Josef R.

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Suelberg, Heiko"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:10:22Z"],["dc.date.available","2018-11-07T09:10:22Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009804441"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26471"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","992"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","999"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Weiss, Christian"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Rau, Tillman"],["dc.contributor.author","Dellas, Kathrin"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:17:13Z"],["dc.date.available","2018-11-07T09:17:13Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose: We have previously shown that the addition of cetuximab to chemoradiation therapy failed to improve complete response rates (pCR) in rectal cancer. Here we report the long-term results of the cetuximab added to preoperative radiation therapy with capecitabine and oxaliplatin (CET-CAPOX-RT) phase 1/2 study that evaluated preoperative chemoradiation with cetuximab, capecitabine, and oxaliplatin in patients with rectal cancer. Methods and Materials: The median follow-up was 63 months (range, 5-73 months). Sixty patients were enrolled; 3 patients were excluded due to protocol violation, and 4 died before surgery. Total mesorectal excision was performed in 53 patients, in 85% (n=45) with curative intention (M0-status). Secondary end points including overall survival (OS) disease-free survival (DFS) and cancer-specific survival (CSS) were calculated. The prognostic value of KRAS mutation status was also assessed. Results: Histopathological examination confirmed ypUICC stages 0 (n=4; pCR), I (n=17), II (n=10), III (n=14), and IV (n=8). For patients who underwent surgery (n=53), OS at 1, 3, and 5 years was 88.7%, 83%, and 75.5%, respectively, whereas CSS rates were 94.1%, 88.1%, and 78.1%, respectively. In the 45 patients who were treated with curative intent (M0), the OS rates at 1, 3, and 5 years were 91.1%, 88.9%, and 86.7%, respectively; whereas CSS rates were 97.6%, 95.2%, and 90.3%, respectively; and DFS rates were 90.7%, 88.3%, and 88.3%, respectively. We did not find any locoregional failure in patients with M0-status (n=45). Chronic toxicity was rare. KRAS mutations, as detected in 33.3%, showed no correlation with the clinicopathological parameters nor significance for either OS (P=.112), CSS (P=.264), or DFS (P=.565). Conclusions: Taken together, chemoradiation therapy combined with cetuximab is safe, feasible, and offers excellent survival rates. KRAS mutation status was not a predictive factor. Importantly, lack of improvement in pCR rate did not translate to poor survival in our clinical trial. (C) 2013 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2013.09.011"],["dc.identifier.isi","000327496600030"],["dc.identifier.pmid","24210078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28108"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","Preoperative Chemoradiation Therapy With Capecitabine/Oxaliplatin and Cetuximab in Rectal Cancer: Long-Term Results of a Prospective Phase 1/2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]